Reprograming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis
Hepatocellular carcinoma (HCC) is the most prevalent and highly aggressive liver malignancy with limited therapeutic options. Here, the therapeutic potential of zerumbone, a sesquiterpene derived from the ginger plant , against HCC was explored. Zerumbone inhibited proliferation and clonogenic survi...
Uloženo v:
| Vydáno v: | Molecular cancer research Ročník 16; číslo 2; s. 256 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.02.2018
|
| Témata: | |
| ISSN: | 1557-3125, 1557-3125 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Hepatocellular carcinoma (HCC) is the most prevalent and highly aggressive liver malignancy with limited therapeutic options. Here, the therapeutic potential of zerumbone, a sesquiterpene derived from the ginger plant
, against HCC was explored. Zerumbone inhibited proliferation and clonogenic survival of HCC cells in a dose-dependent manner by arresting cells at the G
-M phase and inducing apoptosis. To elucidate the underlying molecular mechanisms, a phosphokinase array was performed that showed significant inhibition of the PI3K/AKT/mTOR and STAT3 signaling pathways in zerumbone-treated HCC cells. Gene expression profiling using microarray and analysis of microarray data by Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) revealed that zerumbone treatment resulted in significant deregulation of genes regulating apoptosis, cell cycle, and metabolism. Indeed, tracing glucose metabolic pathways by growing HCC cells with
C
-glucose and measuring extracellular and intracellular metabolites by 2D nuclear magnetic resonance (NMR) spectroscopy showed a reduction in glucose consumption and reduced lactate production, suggesting glycolytic inhibition. In addition, zerumbone impeded shunting of glucose-6-phosphate through the pentose phosphate pathway, thereby forcing tumor cells to undergo cell-cycle arrest and apoptosis. Importantly, zerumbone treatment suppressed subcutaneous and orthotopic growth and lung metastasis of HCC xenografts in immunocompromised mice. In conclusion, these findings reveal a novel and potentially effective therapeutic strategy for HCC using a natural product that targets cancer cell metabolism.
Dietary compounds, like zerumbone, that impact cell cycle, apoptosis, and metabolic processes may have therapeutic benefits for HCC patients.
. |
|---|---|
| AbstractList | Hepatocellular carcinoma (HCC) is the most prevalent and highly aggressive liver malignancy with limited therapeutic options. Here, the therapeutic potential of zerumbone, a sesquiterpene derived from the ginger plant Zingiber zerumbet, against HCC was explored. Zerumbone inhibited proliferation and clonogenic survival of HCC cells in a dose-dependent manner by arresting cells at the G2-M phase and inducing apoptosis. To elucidate the underlying molecular mechanisms, a phosphokinase array was performed that showed significant inhibition of the PI3K/AKT/mTOR and STAT3 signaling pathways in zerumbone-treated HCC cells. Gene expression profiling using microarray and analysis of microarray data by Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) revealed that zerumbone treatment resulted in significant deregulation of genes regulating apoptosis, cell cycle, and metabolism. Indeed, tracing glucose metabolic pathways by growing HCC cells with 13C6-glucose and measuring extracellular and intracellular metabolites by 2D nuclear magnetic resonance (NMR) spectroscopy showed a reduction in glucose consumption and reduced lactate production, suggesting glycolytic inhibition. In addition, zerumbone impeded shunting of glucose-6-phosphate through the pentose phosphate pathway, thereby forcing tumor cells to undergo cell-cycle arrest and apoptosis. Importantly, zerumbone treatment suppressed subcutaneous and orthotopic growth and lung metastasis of HCC xenografts in immunocompromised mice. In conclusion, these findings reveal a novel and potentially effective therapeutic strategy for HCC using a natural product that targets cancer cell metabolism.Implications: Dietary compounds, like zerumbone, that impact cell cycle, apoptosis, and metabolic processes may have therapeutic benefits for HCC patients. Mol Cancer Res; 16(2); 256-68. ©2017 AACR.Hepatocellular carcinoma (HCC) is the most prevalent and highly aggressive liver malignancy with limited therapeutic options. Here, the therapeutic potential of zerumbone, a sesquiterpene derived from the ginger plant Zingiber zerumbet, against HCC was explored. Zerumbone inhibited proliferation and clonogenic survival of HCC cells in a dose-dependent manner by arresting cells at the G2-M phase and inducing apoptosis. To elucidate the underlying molecular mechanisms, a phosphokinase array was performed that showed significant inhibition of the PI3K/AKT/mTOR and STAT3 signaling pathways in zerumbone-treated HCC cells. Gene expression profiling using microarray and analysis of microarray data by Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) revealed that zerumbone treatment resulted in significant deregulation of genes regulating apoptosis, cell cycle, and metabolism. Indeed, tracing glucose metabolic pathways by growing HCC cells with 13C6-glucose and measuring extracellular and intracellular metabolites by 2D nuclear magnetic resonance (NMR) spectroscopy showed a reduction in glucose consumption and reduced lactate production, suggesting glycolytic inhibition. In addition, zerumbone impeded shunting of glucose-6-phosphate through the pentose phosphate pathway, thereby forcing tumor cells to undergo cell-cycle arrest and apoptosis. Importantly, zerumbone treatment suppressed subcutaneous and orthotopic growth and lung metastasis of HCC xenografts in immunocompromised mice. In conclusion, these findings reveal a novel and potentially effective therapeutic strategy for HCC using a natural product that targets cancer cell metabolism.Implications: Dietary compounds, like zerumbone, that impact cell cycle, apoptosis, and metabolic processes may have therapeutic benefits for HCC patients. Mol Cancer Res; 16(2); 256-68. ©2017 AACR. Hepatocellular carcinoma (HCC) is the most prevalent and highly aggressive liver malignancy with limited therapeutic options. Here, the therapeutic potential of zerumbone, a sesquiterpene derived from the ginger plant , against HCC was explored. Zerumbone inhibited proliferation and clonogenic survival of HCC cells in a dose-dependent manner by arresting cells at the G -M phase and inducing apoptosis. To elucidate the underlying molecular mechanisms, a phosphokinase array was performed that showed significant inhibition of the PI3K/AKT/mTOR and STAT3 signaling pathways in zerumbone-treated HCC cells. Gene expression profiling using microarray and analysis of microarray data by Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) revealed that zerumbone treatment resulted in significant deregulation of genes regulating apoptosis, cell cycle, and metabolism. Indeed, tracing glucose metabolic pathways by growing HCC cells with C -glucose and measuring extracellular and intracellular metabolites by 2D nuclear magnetic resonance (NMR) spectroscopy showed a reduction in glucose consumption and reduced lactate production, suggesting glycolytic inhibition. In addition, zerumbone impeded shunting of glucose-6-phosphate through the pentose phosphate pathway, thereby forcing tumor cells to undergo cell-cycle arrest and apoptosis. Importantly, zerumbone treatment suppressed subcutaneous and orthotopic growth and lung metastasis of HCC xenografts in immunocompromised mice. In conclusion, these findings reveal a novel and potentially effective therapeutic strategy for HCC using a natural product that targets cancer cell metabolism. Dietary compounds, like zerumbone, that impact cell cycle, apoptosis, and metabolic processes may have therapeutic benefits for HCC patients. . |
| Author | Wani, Nissar Ahmad Barajas, Juan M Jacob, Samson T Hu, Peng Teng, Kun-Yu Zhang, Bo Yu, Lianbo Brüschweiler, Rafael Ghoshal, Kalpana Motiwala, Tasneem |
| Author_xml | – sequence: 1 givenname: Nissar Ahmad surname: Wani fullname: Wani, Nissar Ahmad organization: Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio – sequence: 2 givenname: Bo surname: Zhang fullname: Zhang, Bo organization: Department of Chemistry & Biochemistry, The Ohio State University, Columbus, Ohio – sequence: 3 givenname: Kun-Yu surname: Teng fullname: Teng, Kun-Yu organization: Department of Pathology, The Ohio State University, Columbus, Ohio – sequence: 4 givenname: Juan M surname: Barajas fullname: Barajas, Juan M organization: Department of Pathology, The Ohio State University, Columbus, Ohio – sequence: 5 givenname: Tasneem surname: Motiwala fullname: Motiwala, Tasneem organization: Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio – sequence: 6 givenname: Peng surname: Hu fullname: Hu, Peng organization: Department of Pathology, The Ohio State University, Columbus, Ohio – sequence: 7 givenname: Lianbo surname: Yu fullname: Yu, Lianbo organization: Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio – sequence: 8 givenname: Rafael surname: Brüschweiler fullname: Brüschweiler, Rafael organization: Campus Chemical Instrument Center (CCIC) NMR, The Ohio State University, Columbus, Ohio – sequence: 9 givenname: Kalpana surname: Ghoshal fullname: Ghoshal, Kalpana email: kalpana.ghoshal@osumc.edu, samson.jacob@osumc.edu organization: Department of Pathology, The Ohio State University, Columbus, Ohio – sequence: 10 givenname: Samson T surname: Jacob fullname: Jacob, Samson T email: kalpana.ghoshal@osumc.edu, samson.jacob@osumc.edu organization: Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29187559$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtLw0AYRQdR7EN_gpKlm9R5ZF5LKdoKLYWqGzdhZvJNiSSZOJMs-u8tWMHVvYvD5XBn6LILHSB0R_CCEK4eCS9ILqUSi-1ynxOZY4aLCzQlnMucEcov__UJmqX0hTHFRIprNKGaKMm5nqLdHvoYDtG0dXfIgs9WzehCgmwLg7GhqVOb2WP2CXFs7ckgexv7PkJKkLI19GYIzkRXd-EAHaQ63aArb5oEt-eco4-X5_flOt_sVq_Lp03eU10MeeXBFBZ7wZQFTgyh2DBvpBeqcth58JUCDRYEtYo6LjTXTDjLHOaMForO0cPv7sn-e4Q0lG2dHDSN6SCMqSRaYsGoZvqE3p_R0bZQlX2sWxOP5d8J9AecEWMq |
| ContentType | Journal Article |
| Copyright | 2017 American Association for Cancer Research. |
| Copyright_xml | – notice: 2017 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/1541-7786.MCR-17-0304 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1557-3125 |
| ExternalDocumentID | 29187559 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA016058 – fundername: NCI NIH HHS grantid: R01 CA086978 – fundername: NCI NIH HHS grantid: R01 CA193244 |
| GroupedDBID | --- .55 .GJ 123 18M 2FS 2WC 34G 39C 3O- 53G 5RE 5VS AAJMC ABEFU ACGFO ACPRK ADBBV ADCOW AENEX AFFNX AFHIN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GX1 H13 HH5 H~9 IH2 KQ8 L7B MVM NPM OK1 QTD RCR RHF RHI TR2 W8F WHG WOQ X7M YKV ZGI 7X8 |
| ID | FETCH-LOGICAL-p294t-dfea4b0f638be51a120a3fa7f68dc0cfefd8e9ebe62b82c5695936cb3c0532482 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 34 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000424053200007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1557-3125 |
| IngestDate | Wed Oct 01 13:36:24 EDT 2025 Wed Feb 19 02:27:39 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | 2017 American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p294t-dfea4b0f638be51a120a3fa7f68dc0cfefd8e9ebe62b82c5695936cb3c0532482 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 29187559 |
| PQID | 1970632939 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1970632939 pubmed_primary_29187559 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-02-01 |
| PublicationDateYYYYMMDD | 2018-02-01 |
| PublicationDate_xml | – month: 02 year: 2018 text: 2018-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular cancer research |
| PublicationTitleAlternate | Mol Cancer Res |
| PublicationYear | 2018 |
| References | 34987114 - Mol Cancer Res. 2022 Jan;20(1):176 |
| References_xml | – reference: 34987114 - Mol Cancer Res. 2022 Jan;20(1):176 |
| SSID | ssj0020176 |
| Score | 2.4079401 |
| Snippet | Hepatocellular carcinoma (HCC) is the most prevalent and highly aggressive liver malignancy with limited therapeutic options. Here, the therapeutic potential... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 256 |
| SubjectTerms | Animals Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism Cell Cycle - drug effects Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Dose-Response Relationship, Drug Gene Expression Profiling - methods Gene Regulatory Networks - drug effects Glucose - metabolism Glycolysis - drug effects Hep G2 Cells Humans Liver Neoplasms - drug therapy Liver Neoplasms - genetics Liver Neoplasms - metabolism Male Mice Sesquiterpenes - administration & dosage Sesquiterpenes - pharmacology Signal Transduction - drug effects Xenograft Model Antitumor Assays |
| Title | Reprograming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29187559 https://www.proquest.com/docview/1970632939 |
| Volume | 16 |
| WOSCitedRecordID | wos000424053200007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qVLz4Mb_mFxG8xrVZ2zQnkeHcwc4hCsNLadJEBq6dayfsv_el6fQkCF56a1NeXt7vfeX9ELqCuMftCOYRJ0lMgMIEEeAIkyCQWgaKBY4dkvTABoNwNOLDOuFW1G2VS5tYGeo0lyZH3nY5AzQFcOI30w9iWKNMdbWm0FhFDViSG61mo-8qAmBbRS4HkGlycdSvb_C4ftgGz8ElZnbaddR9ImCpTYnwdy-zQpvezn__cxdt134mvrWKsYdWVNZEG5Z5ctFEm1FdU99Hj-CD2yYtQDGca3xvu9hxpErQkPdxMcFigV_VbD4ReaawIQKtRo4XuA9gVgIazuBT-Zsxm-PiAL307p67fVLTLJAp5V5JUq0STzgaTqJQvpu41Ek6OmE6CFPpSK10GioOmx1QEVLpB2aWcSBFRxpWCS-kh2gtg-WPEWbMl8KjYGCV8MBZ5JppsJ8Q46TU1Ylqocul0GJQY1ObSDKVz4v4R2wtdGQlH0_tvI2YcheiKp-f_OHtU7QF2x7avuoz1NBwiNU5Wpef5biYXVT6Ac_BMPoCnuzE2w |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reprograming+of+Glucose+Metabolism+by+Zerumbone+Suppresses+Hepatocarcinogenesis&rft.jtitle=Molecular+cancer+research&rft.au=Wani%2C+Nissar+Ahmad&rft.au=Zhang%2C+Bo&rft.au=Teng%2C+Kun-Yu&rft.au=Barajas%2C+Juan+M&rft.date=2018-02-01&rft.issn=1557-3125&rft.eissn=1557-3125&rft.volume=16&rft.issue=2&rft.spage=256&rft_id=info:doi/10.1158%2F1541-7786.MCR-17-0304&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-3125&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-3125&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-3125&client=summon |